Want to see HAE full AI Analyst Report?
Total Valuation
Haemonetics has a market cap or net worth of $4.00B. The enterprise value is $3.53K.
Market Cap$4.00B
Enterprise Value$3.53K
Share Statistics
Haemonetics has 45,497,050 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding45,497,050
Owned by Insiders1.83%
Owned by Institutions8.43%
Financial Efficiency
Haemonetics’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 8.66%.
Return on Equity (ROE)0.12
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)8.66%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee443.35K
Profits Per Employee32.34K
Employee Count3,009
Asset Turnover0.56
Inventory Turnover1.93
Valuation Ratios
The current PE Ratio of Haemonetics is 42.6. Haemonetics’s PEG ratio is -0.69.
PE Ratio42.6
PS Ratio1.91
PB Ratio3.20
Price to Fair Value3.20
Price to FCF9.79
Price to Operating Cash Flow12.14
PEG Ratio-0.69
Income Statement
In the last 12 months, Haemonetics had revenue of 1.33B and earned 97.31M in profits. Earnings per share was 2.05.
Revenue1.33B
Gross Profit743.59M
Operating Income241.40M
Pretax Income128.03M
Net Income97.31M
EBITDA312.45M
Earnings Per Share (EPS)2.05
Cash Flow
In the last 12 months, operating cash flow was 328.15M and capital expenditures -36.93M, giving a free cash flow of 291.22M billion.
Operating Cash Flow328.15M
Free Cash Flow291.22M
Free Cash Flow per Share6.40
Dividends & Yields
Haemonetics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.50
52-Week Price Change67.41%
50-Day Moving Average76.68
200-Day Moving Average68.53
Relative Strength Index (RSI)70.64
Average Volume (3m)720.82K
Important Dates
Haemonetics upcoming earnings date is Nov 5, 2026, Before Open (Confirmed).
Last Earnings DateAug 6, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
Haemonetics as a current ratio of 2.95, with Debt / Equity ratio of 140.26%
Current Ratio2.95
Quick Ratio1.87
Debt to Market Cap0.48
Net Debt to EBITDA3.13
Interest Coverage Ratio8.41
Taxes
In the past 12 months, Haemonetics has paid 30.72M in taxes.
Income Tax30.72M
Effective Tax Rate0.24
Enterprise Valuation
Haemonetics EV to EBITDA ratio is 11.29, with an EV/FCF ratio of 13.55.
EV to Sales2.65
EV to EBITDA11.29
EV to Free Cash Flow13.55
EV to Operating Cash Flow12.03
Balance Sheet
Haemonetics has $223.38M in cash and marketable securities with $1.17B in debt, giving a net cash position of -$950.77M billion.
Cash & Marketable Securities$223.38M
Total Debt$1.17B
Net Cash-$950.77M
Net Cash Per Share-$20.90
Tangible Book Value Per Share-$6.52
Margins
Gross margin is 57.38%, with operating margin of 18.10%, and net profit margin of 7.29%.
Gross Margin57.38%
Operating Margin18.10%
Pretax Margin9.60%
Net Profit Margin7.29%
EBITDA Margin23.42%
EBIT Margin11.75%
Analyst Forecast
The average price target for Haemonetics is $93.57, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$93.57
Price Target Upside18.78% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast0.44%
EPS Growth Forecast-37.48%